Safety and Tolerability of Zilebesiran, an RNA Interference Therapeutic Targeting Hepatic
Angiotensinogen Synthesis, in Obese Pa Page 1 1 #AHA23 SUSTAINED BLOOD PRESSURE …

Consistent Antihypertensive Efficacy of the RNA Interference Therapeutic Zilebesiran:
Subgroup Results from the KARDIA-1 Phase 2 Page 1 Manish Saxena1,2, Akshay S Desai3 …

Importance Angiotensinogen is the most upstream precursor of the renin–angiotensin–
aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an …

Background Angiotensinogen is the sole precursor of angiotensin peptides and has a key
role in the pathogenesis of hypertension. Zilebesiran, an investigational RNA interference …

Objective: Zilebesiran is an investigational RNA interference therapeutic that targets hepatic
angiotensinogen, the most upstream precursor of the renin-angiotensin system. In the Phase …

Arterial hypertension is the most common cardiovascular risk factor in the world. The
prevalence of hypertension has doubled over the last 30 years. Despite the availability of …

New data from a phase 1 clinical trial suggest that the small-interfering RNA (siRNA)
therapeutic zilebesiran could be beneficial in patients with hypertension. Zilebesiran is …

Hypertension is a considerable cause of morbidity and mortality across the globe. It is
estimated to contribute either directly or indirectly to one out of every eight deaths worldwide …

We aim to summarize selected late-breaking science on hypertension management
strategies and disease presented at the 2023 American Heart Association (AHA) …

Patients with hypertension who receive a single subcutaneous dose of zilebesiran, a novel
small-interfering RNA that inhibits hepatic angiotensinogen synthesis, have reductions in …